Navigation Links
Twin study reveals epigenetic alterations of psychiatric disorders
Date:9/21/2011

In the first study to systematically investigate genome-wide epigenetic differences in a large number of psychosis discordant twin-pairs, research at the Institute of Psychiatry (IoP) at King's College London provides further evidence that epigenetic processes play an important role in neuropsychiatric disease. Published in Human Molecular Genetics, the findings may offer potential new avenues for treatment.

Previous quantitative genetic analyses of schizophrenia and bipolar disorder reveal strong inherited components to both. However, although heritability for schizophrenia and bipolar disorder is estimated at 70%, disease concordance between twin-pairs is far from 100%, indicating that non-genetic factors play an important role in the onset of the diseases.

Dr. Jonathan Mill, lead author of the study at the IoP says, 'We studied a group of 22 identical twin-pairs, so 44 individuals in all, one of the largest twin studies performed for any complex disease to date. In each twin-pair, one had either schizophrenia or bipolar disorder. Because we know that twins are genetically identical, we can rule out any genetic cause of illness in the affected twin the aim of our study was to investigate epigenetic variations associated with these disorders.'

Epigenetic mechanisms are linked to heritable, but reversible, changes in gene expression without a change in the underlying DNA sequence. This happens principally through alterations in DNA methylation and chromatin structure. Epigenetic changes in the brain have previously been associated with a range of biological and cognitive processes, including neurogenesis, drug addiction and neurodegeneration. It has also been suggested that epigenetic changes in the brain may be involved in a spectrum of psychiatric disorders including psychosis.

The researchers looked at differences in DNA methylation across the genome using DNA taken from both the affected and unaffected twins in each monozygotic twin-pair. The findings were then compared to DNA samples taken from post-mortem brain material from psychosis patients and controls.

Whilst the researchers found no alterations in overall DNA methylation content between affected and unaffected twins, there were considerable disease-associated differences between twins at specific sites across the genome. The findings confirmed previously known sites implicated in psychiatric disorders as well as revealing previously unknown ones.

Dr. Mill adds, 'Our findings suggest that it is not only genetic variations that are important. The epigenetic differences we see may tell us more about the causes or schizophrenia and bipolar disorder, as some alterations were specific to either disease. Importantly, epigenetic processes are potentially reversible meaning that our research could open up new avenues for the development of novel therapeutic drugs.'


'/>"/>
Contact: Seil Collins
seil.collins@kcl.ac.uk
44-020-784-85377
King's College London
Source:Eurekalert

Related biology news :

1. Long-term study shows effect of climate change on animal diversity
2. £2 million study to reveal workings of dementia genes
3. New study looks to define evangelicals and how they affect polling
4. CU-Boulder study suggests air quality regulations miss key pollutants
5. Researchers study acoustic communication in deep-sea fish
6. Study reveals homeowner perceptions in fire-prone areas
7. Researchers study how pistachios may improve heart health
8. Study: urban black bears live fast, die young
9. New study indicates link between weight gains during pregnancy and dieting history
10. Study reveals specific gene in adolescent men with delinquent peers
11. Sweat it out: UH study examines ability of sweat patches to monitor bone loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/28/2017)...   Acuant , a leading provider of data ... to new and core technologies building upon the acquisition ... and desktop Acuant FRM TM facial recognition and ... time manual review of identity documents by accredited professionals. ... and most accurate capture software to streamline workflows by ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... York , March 22, 2017 ... largely fragmented, states a research report by Transparency Market ... Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for ... 2015. The prominent players in this market are focusing ... their product portfolio, which is likely to lead to ...
Breaking Biology Technology: